Explore the Agenda
8:00 am Check In & Coffee
8:50 am Chair’s Opening Remarks
Evaluating the Current T-Cell Engager Landscape to Apply Lessons Learnt from Hematology to Solid Tumors & Autoimmune Disease
9:00 am Opening Panel Discussion: Reflecting on Past Successes & Future Challenges Across the T-Cell Engager Landscape
- Reflecting on the move away from first generation BiTE molecules to next-generation logic-gated and multi-specific T cell engagers
- Exploring advancements in preclinical and clinical modelling of TCEs to allow for improvements in efficacy whilst minimizing system toxicity
- Evaluating the potential for TCEs to serve as a scalable, off-the-shelf alternative to personalized CAR-T therapies
9:30 am T-Cell Engager Landscape
- Exploring the latest developments shaping the T-cell engager landscape.
- Highlighting which mechanisms, scaffolds, and targets have established themselves and which are emerging.
- Analyzing where T-cell engager development is heading next, and what to watch.
10:00 am Navigating the Early Clinical Hurdles of T-Cell Engagers in Solid Tumors
- Exploring strategies for widening the therapeutic index in solid tumors, focusing of affinity tuning of CD3 arm and the implementation of logic-gated architectures to protect healthy tissues
- Overcoming physical and metabolic barriers of solid tumor core by integrating costimulatory signals
- Utilizing context-dependent engagers that are only active in hypoxic or acidic conditions
10:30 am Speed Networking
Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in the T-Cell Engager field. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and technique applications.
11:00 am Morning Refreshments & Networking
Discovery, Design & Engineering
Innovating Accurate Molecular Engineering to Balance Potency & Toxicity to Optimize Therapeutic Index
11:30 am Engineering Co-Stimulation for Mitigating Systemic Toxicity & Maximising Localized T-Cell Activation
- Evaluating risk-benefit profile associated with systemic costimulatory receptor engagement
- Analyzing molecular design where co-stimulatory activation depends on signal 1 engagement to ensure T-cell proliferation is restricted to the tumor antigen surface
- Examining how tumor associated antigen effects efficacy and cytokine release
12:00 pm Harnessing Avidity-Based Binding Logic to Improve T-cell Engager Selectivity for Solid Tumors
- Integrating high-throughput functional cell-based assays with machine learning to enable rapid optimization of preclinical candidates
- Solving on-target/off-tumor toxicities through avidity-driven tumor selectivity
- Progressing our lead asset LGTX-101 (Nectin-4 x CD3 T-cell engager) through IND enabling studies demonstrating robust in vitro, in vivo and biophysical characteristics
12:30 pm Panel Discussion: Leveraging Early Strategies to Mitigate Clinical Toxicity in TCE Therapeutics
- Exploring design strategies to decouple cytokine production from therapeutic ability to bypass dose-limiting toxicities like CRS without compromising efficacy
- Deep diving into how tumor cells evade detection through antigen escape and the development of next-generation engagers designed to maintain long-term pressure on cold tumors
- Determining the optimal level of antigen expression required for clinical success
Preclinical & Translational Development
Overcoming Therapeutic Resistance by Engineering Adaptive Immune Engagers to Transform Tumor Outcomes
11:30 am Expanding the Reach of T Cell Engagers in Solid Tumors through pMHC Multi-Targeting
- Addressing the fundamental challenge of low pMHC copy number and target heterogeneity that limits TCE efficacy in solid tumors through multi-pMHC recognition strategies
- Demonstrating how engineered TCRs can recognize multiple cancer-restricted pMHCs through shared structural motifs, enabling potent T cell activation at sub-10 pM EC50s while maintaining specificity
- Establishing comprehensive specificity de-risking approaches using sequence-agnostic, immunopeptidomics-based screening across >13,000 healthy tissue peptides to support broad application across major solid tumor indications
12:00 pm Leveraging Single-Cell Sequencing to Identify Highly Precise Single and Combination T-Cell Engager Targets
- Highlighting the central challenge in solid tumor T-cell engagers: identifying clean targets with high tumor specificity
- Cartography’s ATLAS platform: applying single-cell RNA sequencing to map tumor antigen expression and identify tumor-restricted antigens with broad patient coverage
- Discovery and advancement of CBI-1214, a T-cell engager targeting LY6G6D, a highly tumor-restricted colorectal cancer antigen entering the clinic in early 2026
- Extending this framework to multi-specific and AND-gated T-cell engagers through the SUMMIT platform, enabling identification of target pairs that further enhance therapeutic index
12:30 pm Panel Discussion: Translating Mechanistic Insights into Effector Durability through Mitigating T-Cell Exhaustion
- Analyzing whether mass changes in peripheral T-cell capacity serve as a predictive biomarker for clinical response r a signature of therapeutic failure
- Identifying points where TCEs fail to maintain sustained cytotoxic pressure and harnessing these insights to inform the timing of TCE administration
- Understanding how chronic antigen exposure under TCE stimulation drives effector dysfunction and how these findings can be used to engineer more resilient T-cell therapies
1:00 pm Lunch & Networking
Discovery, Design & Engineering
Enhancing Immune Persistence by Integrating Site-Specific Co-stimulation to Achieve Durable & Targeted Anti-Tumor Responses
2:00 pm Dual-Antigen Targeting & Co-Stimulation to Overcome Resistance & Antigen-Escape in Next Generation Multi- Specifics
- Translating the success of CD19/CD20 bispecific T-cell engager space by targeting two tumor-associated antigens simultaneously to ensure efficacy event when one antigen is downregulated
- Discussing strategies for incorporating co-stimulatory domains into multi-specific designs to enhance the depth and durability of clinical responses beyond what is possible with CD3 engagement alone
- Addressing the structural hurdles of trispecific and multispecific molecules whilst maintaining manufacturability and acceptable cost of goods
2:30 pm Panel Discussion: Breaking the Efficacy Ceiling with Strategies to Enhance Depth & Durability in Next- Generation T-Cell Engagers
- Analyzing recent clinical readouts to understand why safety optimized molecules often encounter an efficacy plateau and identifying the biological drivers behind limited therapeutic depth
- Evaluating the integration of signal 2 to overcome the efficacy ceiling, moving from transient T-cell activation to sustained, robust anti-tumor responses
- Utilizing advanced biomarker strategies to identify patientspecific T-cell characterises and TME features that predict which individuals will achieve durable remissions
Preclinical & Translational Development
Accelerating Clinical Readiness by Implementing Advanced Predictive Modelling to Navigate an Evolving Regulatory Environment
2:00 pm A PSMA-Targeted, CD2-Costimulating T-Cell Engager with Strong Preclinical Efficacy & a Favorable GLP Toxicology Profile
- PSMA is highly expressed in prostate cancer, and single‑cell RNA sequencing of metastatic tumor‑infiltrating lymphocytes identifies CD2 as a broadly expressed co‑stimulatory receptor, particularly on CD8⁺ T cells
- QL535, a trispecific PSMA × CD3 × CD2 molecule (2+1+1 TECOS format), delivers CD3 activation and CD2 co‑stimulation to enhance cytotoxicity while limiting cytokine release compared with benchmark T‑cell engagers
- QL535 demonstrates superior PSMA‑dependent killing in vitro, sustained activity under repeated stimulation, dose‑responsive tumor regression in PSMA⁺ PDX PDX models, and a favorable GLP toxicology profile in non‑human primates, supporting its clinical development for PSMA‑positive prostate cancer
2:30 pm Panel Discussion: Standardizing Safety Benchmarks by Establishing Collaborative In Vitro Frameworks to De- Risk T-Cell Engager Translation
- Addressing the lack of commercialized GLP-standardized assays for pHLA and human-specific targets, and the resulting necessity for companies to develop bespoke, creative in-house solutions
- Evaluating current industry best practices by analyzing the non-clinical pathways of pioneers to establish a common technical foundation for the field
- Proposing collaborative strategies to share methodologies and validation data for in vitro assays to help move the industry toward a unified standard that can be more effectively presented to regulatory bodies
3:00 pm Scientific Poster Session
Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversations and discussions. Explore a range of exciting poster presentations and showcase your own developments in the TCE world. Don’t miss out on the chance to submit your own posters and get ready to connect, learn, and present. To submit your poster please contact info@hansonwade.com
Lessons Learnt from Haematology to Inform Novel Costimulatory Strategies for Solid Tumors
4:00 pm Translating Haematology’s Successes: Leveraging Immune Costimulation Lessons to Advance Solid Tumor Therapies
- Establishing the clinical PoM for two distinct costimulators, Englumafusp alfa (4-1BB) and CD28, in combination with Glofitamab for r/r NHL, showing how each engages a unique immunologic pathway
- Presents biomarker evidence (e.g., peripheral memory T‑cell expansion, ctDNA reduction) linking 4‑1BB to durable, late responses and CD28 to rapid, early tumor killing
- Identifies tumor microenvironment profiles where each costimulatory pathway performs optimally, supporting more personalized treatment selection for poor‑prognosis patients
4:30 pm Session Reserved for WuXi Biologics
5:00 pm BEAT®: A Platform To Advance Developable Multispecific Therapeutic Antibodies To The Clinic
- The flexible BEAT® platform enables 5 or more functional modules to be combined into a single molecule with excellent manufacturability and developability
- This platform has been clinically validated by demonstrating superior efficacy, low immunogenicity in humans and good pharmacokinetics
- The biophysical plus functional screening and precision engineering required to generate MultispecificTM immune engagers advancing to the clinic to treat haematological and solid cancers will be described.
5:30 pm Revolutionizing Solid Tumor Care by Applying Haematology‑Driven Insights to Optimize Clinical Delivery and Dosing
- Extracting key lessons from haematology’s shift in delivery models, including the transition from traditional IV regimens to streamlined subcutaneous approaches, and understanding how these changes have improved patient experience, clinic efficiency, and therapeutic consistency
- Leveraging haematology’s established frameworks for step‑up dosing, toxicity mitigation, and response monitoring, exploring how these principles can be adapted to solid tumor therapies to improve safety, manage CRS and related immune toxicities, and support broader outpatient administration
- Examining real‑world evidence and clinical learnings from haematology agents such as bispecifics and T‑cell engagers, and assessing how these insights are shaping the clinical deployment, exposure management, and dose optimization of emerging solid‑tumor agents, highlighting Tarlatamab and next‑generation molecules as examples of iterative improvement driving enhanced patient outcomes